Affimed's Innovative Cancer Research Featured at ASCO Meeting
Affimed Takes Center Stage at ASCO Annual Meeting
Affimed N.V. (Nasdaq: AFMD), a pioneering clinical-stage immuno-oncology company, has some thrilling news to share about its participation in an important event in the medical field. The company has received great recognition with the acceptance of three abstracts for presentation at the prestigious American Society for Clinical Oncology (ASCO) Annual Meeting, scheduled to take place from May 30 to June 3. This meeting serves as a key platform for showcasing the latest advancements in cancer treatment, and Affimed's contributions highlight its continued commitment to developing innovative therapies that empower patients to harness their inherent ability to combat cancer.
Highlight on Clinical Studies
Among the notable presentations, one abstract focuses on the phase 2 LuminICE-203 study of Affimed's innate cell engager (ICE) acimtamig in conjunction with AlloNK (AB-101). This is an oral presentation that aims to shed light on promising results from studies involving patients with classical Hodgkin lymphoma who have experienced relapses or refractory conditions. Audiences at the conference can look forward to detailed findings regarding this innovative approach in treating challenging lymphoma cases.
Oral Presentation Details
The oral presentation will take place on May 30, during the Oral Abstract Session dedicated to Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia. Attendees will learn about the clinical implications of the combination therapy between the innate cell engager acimtamig and AlloNK, which has been developed to potentially enhance therapeutic outcomes in patients.
Two Posters on NSCLC Research
In addition to the oral presentation, Affimed is also set to present two significant posters focusing on its bispecific innate cell engager AFM24 combined with atezolizumab—another promising therapy for patients battling non-small cell lung cancer (NSCLC). The posters will delve into the initial results from a phase 2a study, underlining the potential of this combination, particularly in cases involving advanced or metastatic NSCLC.
Poster Presentation Highlights
Both poster presentations are scheduled for June 2, from 1:30 PM to 4:30 PM. These sessions will feature:
- Initial results from the combination of AFM24 and atezolizumab in patients without driver mutations.
- Findings related to patients with advanced/metastatic NSCLC with EGFR kinase domain mutations, providing insights that could alter treatment approaches moving forward.
The Significance of ASCO Participation
Participating in the ASCO Annual Meeting represents a crucial opportunity for Affimed to engage with the scientific community, share groundbreaking research, and discuss ongoing advancements in cancer therapies. This event is not just about sharing results; it's also about sparking valuable discussions among healthcare professionals about the future of cancer treatment.
About Affimed N.V.
Affimed is fiercely dedicated to restoring the innate power within patients to fight cancer. Through its innovative approach involving ICE technologies, the company seeks to develop targeted therapies that can significantly enhance the effectiveness of treatments for both hematologic and solid tumors. The ICEs, developed on Affimed's proprietary ROCK platform, are engineered to utilize the innate immune system's capabilities to effectively recognize and destroy cancer cells.
Affimed is situated in Mannheim, Germany, and its experienced leadership team is committed to advancing the frontier of cancer therapeutics, striving to prevent cancer from compromising patients' lives.
Customized Communication
If you're interested in staying updated on Affimed's journey and breakthroughs in cancer treatments, you can learn more about the company, its pipeline, and its dedicated team by visiting their website.
Investor and Media Relations
Investor Relations Contact:
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact:
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
Frequently Asked Questions
What is Affimed's primary focus?
Affimed focuses on developing immuno-oncology therapies that harness the innate immune system to target and eliminate cancerous cells.
What presentations will Affimed give at the ASCO Meeting?
Affimed will present one oral abstract and two poster presentations focusing on innovative therapies for treating Hodgkin lymphoma and non-small cell lung cancer.
When will the ASCO Annual Meeting take place?
The ASCO Annual Meeting will occur from May 30 to June 3, showcasing groundbreaking cancer research.
What is an innate cell engager (ICE)?
An innate cell engager (ICE) is a type of therapy designed to enhance the body's immune response to fight cancer more effectively.
How can I learn more about Affimed's developments?
You can visit Affimed's official website for detailed information about their research, pipeline, and corporate updates.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.